Christoph Säly,

Moderator of 1 Session

Conference Calendar

Late breaker

Late breaker session 1

Session Type

Late breaker

Chair(s)

Christoph Säly,

Room

Hall 1

Date

05.10.2020, Monday

Session Time

16:00 - 17:00

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia","mode":"playlist","public":true,"info":{"id":1707,"presentation":"Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia","session":"Late breaker session 1","presenter":"Frederick J. Raal, South Africa","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal - EAS20 - reduces LDL cholesrerol - 1707.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal - EAS20 - reduces LDL cholesrerol - 1707.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/597DF380.jpg","data":[],"tracks":[]}]},{"name":"Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: Analysis from the Phase III ORION-11 trial","mode":"playlist","public":true,"info":{"id":1701,"presentation":"Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: Analysis from the Phase III ORION-11 trial","session":"Late breaker session 1","presenter":"Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations Analysi","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Kosh Ray EAS20 1701 Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations Analysis from the Phase III ORION-11 trial.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Kosh Ray EAS20 1701 Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations Analysis from the Phase III ORION-11 trial.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/CBB78339.jpg","data":[],"tracks":[]}]},{"name":"The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Activity","mode":"playlist","public":true,"info":{"id":1573,"presentation":"The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Activity","session":"Late breaker session 1","presenter":"Frederick J. Raal, South Africa","photo":""},"playlist":[{"name":"The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients w","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal (Derick) - EAS20- 1573 -The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Ac.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal (Derick) - EAS20- 1573 -The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Ac.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/1AD7F549.jpg","data":[],"tracks":[]}]},{"name":"Results of a 52 week Open-Label Phase 2b Study to Assess Long-term Safety, Immunogenicity and LDL-C Efficacy of Monthly Dosing With LIB003 a novel anti-PCSK9 recombinant fusion protein","mode":"playlist","public":true,"info":{"id":1695,"presentation":"Results of a 52 week Open-Label Phase 2b Study to Assess Long-term Safety, Immunogenicity and LDL-C Efficacy of Monthly Dosing With LIB003 a novel anti-PCSK9 recombinant fusion protein","session":"Late breaker session 1","presenter":"Traci A. Turner, United States of America","photo":""},"playlist":[{"name":"Traci Turner - EAS20 - 1695 - Results of a 52 week Open-Label Phase 2b Study to Assess Long-term Saf","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Traci Turner - EAS20 - 1695 - Results of a 52 week Open-Label Phase 2b Study to Assess Long-term Safety.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Traci Turner - EAS20 - 1695 - Results of a 52 week Open-Label Phase 2b Study to Assess Long-term Safety.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/9B3E7957.jpg","data":[],"tracks":[]}]},{"name":"Bupropion and\/or naltrexone are not associated with increased risk of major adverse cardiovascular events: a network meta-analysis of additive effects","mode":"playlist","public":true,"info":{"id":1667,"presentation":"Bupropion and\/or naltrexone are not associated with increased risk of major adverse cardiovascular events: a network meta-analysis of additive effects","session":"Late breaker session 1","presenter":"Luiz Sergio F. De Carvalho, Brazil","photo":""},"playlist":[{"name":"1667","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/1667 _edit.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/1667 _edit.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/2C888ED6.jpg","data":[],"tracks":[]}]},{"name":"The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian Federation","mode":"playlist","public":true,"info":{"id":1661,"presentation":"The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian Federation","session":"Late breaker session 1","presenter":"Alexey N. Meshkov, Russian Federation","photo":""},"playlist":[{"name":"1661-The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/EAS201661.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/EAS201661.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/D947B915.jpg","data":[],"tracks":[]}]},{"name":"Live Q&A","mode":"playlist","public":true,"info":{"id":1768,"presentation":"Live Q&A","session":"Late breaker session 1","presenter":"Frederick J. Raal, South Africa, Kausik K. Ray, United Kingdom, Evan A. Stein, United States of America, Luiz Sergio F. De Carvalho, Brazil, Alexey N. Meshkov, Russian Federation, Christoph S\u00e4ly, ","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"Late breaker session 1","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Late breaker session 1.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Late breaker session 1.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/A4660C7D.jpg","data":[],"tracks":[]}]}]